Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;25(9):1078-1086.
doi: 10.1111/1756-185X.14388. Epub 2022 Jul 18.

Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis

Júlia Faria Campos  1 , Gustavo Gomes Resende  2 , Alfredo José Afonso Barbosa  3 , Silas Castro de Carvalho  4 , Junia Aguiar Lage  5 , Pedro Ferrari Sales Cunha  5 , Stela Cristina Silva de Souza  5 , Maria de Lourdes Abreu Ferrari  6
Affiliations

Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis

Júlia Faria Campos et al. Int J Rheum Dis. 2022 Sep.

Abstract

Aim: Microscopic bowel inflammation is present in up to 60% of all patients with spondyloarthritis (SpA) and appears to be associated with more severe joint disease and a higher risk of developing inflammatory bowel disease (IBD). This study aimed to determine the utility of fecal calprotectin (fCAL) in evaluating endoscopic and histological bowel inflammation in SpA patients.

Methods: Ileocolonoscopies with biopsies and fCAL measurements were performed in 65 patients with SpA.

Results: In 47 (72.3%) patients, the fCAL levels were higher than 50 μg/g, whereas in 20 (30.7%), these levels were greater than 250 μg/g. A total of 38 (58.5%) patients presented with microscopic bowel inflammation, and 13 (20%) presented with signs of endoscopic inflammation. fCAL levels were significantly higher in patients with microscopic bowel inflammation than in those without inflammatory findings (P < .001); additionally, these levels were slightly higher in patients with endoscopic signs of bowel inflammation (P = .053). A fCAL cutoff value of 96 μg/g predicted histological bowel inflammation with 73% sensitivity and 67% specificity. No statistically significant difference was observed in the fCAL levels between patients who had been treated or not treated with nonsteroidal anti-inflammatory drugs (NSAIDs).

Conclusion: Our findings confirm a high prevalence of microscopic bowel inflammation in SpA patients, regardless of the use of NSAIDs. The evaluation of fCAL levels proved to be useful in the identification of microscopic inflammation and could help in the more judicious indication of ileocolonoscopy. These results support the use of fCAL for the evaluation of microscopic bowel inflammation in SpA patients.

Keywords: ankylosing spondylitis; biomarker; fecal calprotectin; inflammatory bowel disease; spondyloarthritis.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Praet L, Bosch F, Mielants H, Elewaut D. Mucosal Inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep. 2011;13:409-415.
    1. Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-D’Elia H. Calprotectin in ankylosing spondylitis - Frequently elevated in feces, but normal in serum. Scand J Gastroenterol. 2012;47:435-444.
    1. Praet L, Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: A multiparametric predictive model. Ann Rheum Dis. 2013;72:414-417.
    1. Wendling D. The gut in spondyloarthritis. Joint Bone Spine. 2016;83:401-405.
    1. Praet L, Jacques P, Bosch F, Elewaut D. The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol. 2012;8:288-295.

MeSH terms

Substances

LinkOut - more resources